Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 1 October 2020 CORPORATE STATEMENT: Biocartis Joins COVID-19 Testing Industry Consortium of Nineteen Healthcare Community Organizations Non-regulated information 30 September 2020 Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay Non-regulated information 14 September 2020 Large Prospective Lung Cancer Study To Be Presented at ESMO Congress Shows Idylla™ Reduces EGFR Mutation Testing Turnaround Time by More than a Week Non-regulated information 1 September 2020 Biocartis Expands Collaboration with LifeArc Non-regulated information 26 June 2020 US Multicenter Study Shows Idylla™ Allows Rapid and Accurate Mutation Testing Results Across Different Laboratory Settings Non-regulated information 23 April 2020 Biocartis Announces Development of Idylla™ COVID-19 test Non-regulated information 5 March 2020 Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China Non-regulated information 22 January 2020 Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study Non-regulated information 17 December 2019 Biocartis Announces 2020 Financial Calendar Non-regulated information 14 November 2019 Nichirei Biosciences to Initiate Market Introduction of Idylla™ Platform in Japan Non-regulated information Pagination First page « First Previous page ‹‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page ›› Last page Last »